TY - JOUR
T1 - Pegylated interferon-α2a in cutaneous T-cell lymphoma – a multicenter retrospective data analysis with 70 patients
AU - Hansen-Abeck, Inga
AU - Geidel, Glenn
AU - Abeck, Finn
AU - Kött, Julian
AU - Cankaya, Rohat
AU - Dobos, Gabor
AU - Mitteldorf, Christina
AU - Nicolay, Jan P.
AU - Albrecht, Jana D.
AU - Menzer, Christian
AU - Livingstone, Elisabeth
AU - Mengoni, Miriam
AU - Braun, Andreas D.
AU - Wobser, Marion
AU - Klemke, Claus Detlev
AU - Tratzmiller, Sabine
AU - Assaf, Chalid
AU - Terheyden, Patrick
AU - Klespe, Kai Christian
AU - Schneider, Stefan W.
AU - Booken, Nina
N1 - Publisher Copyright:
© 2024 The Author(s). Journal der Deutschen Dermatologischen Gesellschaft published by Wiley-VCH GmbH on behalf of Deutsche Dermatologische Gesellschaft.
PY - 2024/11
Y1 - 2024/11
N2 - Background: Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020, pegylated interferon-α2a (pegIFN-α2a) can be used as an alternative treatment, even though it is not approved for the treatment of CTCL. The aim of this multicentre study was to generate comprehensive data on the efficacy and tolerability of pegIFN-α2a in the treatment of CTCL. Patients and Methods: A multicenter retrospective study was conducted with 70 patients with CTCL from twelve German skin centers. Results: In total, 70 patients were included in the study, with 57.2% male and a mean age of 58.8 ± 14.9 years. Mycosis fungoides was present in 71.4% of cases and Sézary Syndrome in 28.6%. An overall response rate of 55.2% was observed with pegIFNα-2a therapy. In 50% of cases, therapy was discontinued after 63.6 ± 33.5 weeks. The most common reason for discontinuation was adverse events, which occurred in 68.6% of cases and which were classified as severe in 29.2%. Blood count changes, fatigue and liver toxicity occurred most frequently. Conclusions: Our analysis provides comprehensive data on the efficacy and tolerability of pegIFNα-2a therapy in patients with CTCL. In terms of response rates and side effect profile, pegIFNα-2a appears to be comparable to IFN-α2a therapy.
AB - Background: Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020, pegylated interferon-α2a (pegIFN-α2a) can be used as an alternative treatment, even though it is not approved for the treatment of CTCL. The aim of this multicentre study was to generate comprehensive data on the efficacy and tolerability of pegIFN-α2a in the treatment of CTCL. Patients and Methods: A multicenter retrospective study was conducted with 70 patients with CTCL from twelve German skin centers. Results: In total, 70 patients were included in the study, with 57.2% male and a mean age of 58.8 ± 14.9 years. Mycosis fungoides was present in 71.4% of cases and Sézary Syndrome in 28.6%. An overall response rate of 55.2% was observed with pegIFNα-2a therapy. In 50% of cases, therapy was discontinued after 63.6 ± 33.5 weeks. The most common reason for discontinuation was adverse events, which occurred in 68.6% of cases and which were classified as severe in 29.2%. Blood count changes, fatigue and liver toxicity occurred most frequently. Conclusions: Our analysis provides comprehensive data on the efficacy and tolerability of pegIFNα-2a therapy in patients with CTCL. In terms of response rates and side effect profile, pegIFNα-2a appears to be comparable to IFN-α2a therapy.
UR - http://www.scopus.com/inward/record.url?scp=85205353753&partnerID=8YFLogxK
U2 - 10.1111/ddg.15511
DO - 10.1111/ddg.15511
M3 - Journal articles
C2 - 39358932
AN - SCOPUS:85205353753
SN - 1610-0379
VL - 22
SP - 1489
EP - 1497
JO - JDDG - Journal of the German Society of Dermatology
JF - JDDG - Journal of the German Society of Dermatology
IS - 11
ER -
